HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Experimental Leukemia

Subscribe to New Research on Experimental Leukemia

Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.

Also Known As:

Leukemia, Experimental; Experimental Leukemias; Leukemia Model, Animal; Leukemias, Experimental; Animal Leukemia Model; Animal Leukemia Models; Leukemia Models, Animal

Networked: 64 relevant articles (2 outcomes, 8 trials/studies)

Relationship Network

Disease Context: Research Results

Neoplasms: 649836
- Experimental Neoplasms: 47
  - Experimental Leukemia: 64
- Neoplasms by Histologic Type: 1
  - Leukemia: 41436
    - Experimental Leukemia: 64

Related Diseases

1.	Leukemia
2.	Neoplasms (Cancer)
3.	Lymphoma (Lymphomas)
4.	Myeloid Sarcoma (Chloroma)
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

Experts

1.	Reddy, L Harivardhan: 2 articles (08/2008 - 11/2006)
2.	Lepêtre-Mouelhi, Sinda: 2 articles (08/2008 - 11/2006)
3.	Desmaële, Didier: 2 articles (08/2008 - 11/2006)
4.	Dubernet, Catherine: 2 articles (08/2008 - 11/2006)
5.	Couvreur, Patrick: 2 articles (08/2008 - 11/2006)
6.	Prabhu, K Sandeep: 1 article (10/2015)
7.	Quickel, Michael D: 1 article (10/2015)
8.	Whelan, Jay: 1 article (10/2015)
9.	Goodfield, Laura L: 1 article (10/2015)
10.	Kudva, Avinash K: 1 article (10/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Experimental Leukemia:

1.	Eicosapentaenoic AcidIBA 10/01/2015 - "In this study, we supplemented mice with eicosapentaenoic acid (EPA, C20:5), a polyunsaturated omega-3 fatty acid, at pharmacologic levels, to examine whether the endogenous metabolite, cyclopentenone prostaglandin delta-12 PGJ3 (Δ(12)-PGJ3), was effective in targeting LSCs in experimental leukemia. "
2.	cyclopentenoneIBA 10/01/2015 - "In this study, we supplemented mice with eicosapentaenoic acid (EPA, C20:5), a polyunsaturated omega-3 fatty acid, at pharmacologic levels, to examine whether the endogenous metabolite, cyclopentenone prostaglandin delta-12 PGJ3 (Δ(12)-PGJ3), was effective in targeting LSCs in experimental leukemia. "
3.	4-(N)-tris-nor-qualenoyl-gemcitabineIBA 08/01/2008 - "Herein, this paper brings comprehensive pharmacokinetic and biodistribution insights that may explain the previously observed greater efficacy of SQdFdC nanoassemblies against experimental leukemia."
4.	Doxorubicin (Adriamycin)FDA LinkGeneric 11/01/1984 - "In combination therapy, MDL 72175 plus Adriamycin gave at least additive antitumor effects on solid tumors and experimental leukemias in animals. " 01/01/1984 - "Idarubicin (IDR) is a new analog of Daunorubicin (DNR) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to DNR and Doxorubicin. " 03/01/1990 - "Idarubicin is a new derivative of Daunorubicin which was found to be more potent and more active than Daunorubicin and Doxorubicin in several experimental leukemias. " 12/31/1983 - "Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an antitumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. "
5.	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/01/1984 - "Idarubicin (IDR) is a new analog of Daunorubicin (DNR) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to DNR and Doxorubicin. " 03/01/1990 - "Idarubicin is a new derivative of Daunorubicin which was found to be more potent and more active than Daunorubicin and Doxorubicin in several experimental leukemias. " 12/31/1983 - "Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an antitumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. "
6.	Daunorubicin (Cerubidine)FDA LinkGeneric 01/01/1984 - "Idarubicin (IDR) is a new analog of Daunorubicin (DNR) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to DNR and Doxorubicin. " 03/01/1990 - "Idarubicin is a new derivative of Daunorubicin which was found to be more potent and more active than Daunorubicin and Doxorubicin in several experimental leukemias. " 12/31/1983 - "Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an antitumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. "
7.	Glycine Hydroxymethyltransferase (Serine Hydroxymethyltransferase)IBA 03/01/1971 - "[Study of serine hydroxymethyltransferase in experimental leukemias]."
8.	SemustineIBA 01/01/1982 - "Studies on the chemotherapeutic potential of methyl-CCNU on experimental leukemias were undertaken. "
9.	Peptide Hydrolases (Proteases)IBA 09/01/2009 - "These data have shown that lysosomal proteases are involved in progression of murine experimental leukemias and elimination of tumor cells in the result of treatment. " 09/01/2009 - "The present study was designed to investigate activity of cathepsins B, L and D activity in the development and treatment of murine experimental leukemias and to determine the correlation of these proteases with tumor malignancy and the chemotherapy effect. "
10.	CathepsinsIBA 09/01/2009 - "[The lysosomal cathepsins B, L and D in development of murine experimental leukemias]." 09/01/2009 - "The present study was designed to investigate activity of cathepsins B, L and D activity in the development and treatment of murine experimental leukemias and to determine the correlation of these proteases with tumor malignancy and the chemotherapy effect. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/1979 - "[Research results and prospects in the field of experimental leukemia chemotherapy]." 07/01/1974 - "Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex." 09/01/2009 - "The present study was designed to investigate activity of cathepsins B, L and D activity in the development and treatment of murine experimental leukemias and to determine the correlation of these proteases with tumor malignancy and the chemotherapy effect. "
2.	Transplants (Transplant) 01/01/1959 - "[Trial of treatment of experimental leukemia by the graft of normal hematopoietic cells]."
3.	Hematopoietic Stem Cell Transplantation 06/01/2012 - "Mouse model of leukemia hematopoietic stem cell transplantation is the key platform to study leukemia experimental treatment, which has been widely used in anticancer drug screening and in the studies of leukemia pathogenesis and experimental treatment. "
4.	Transplantation (Transplant Recipients) 08/01/1967 - "[Effect of transplantation of spleen cells and administration of spleen extracts on hemopoiesis in experimental leukemia]." 01/01/2015 - "We report a humanized experimental leukemia model where xenografts develop aggressive acute myeloid leukemia (AML) with disseminated myeloid sarcomas within 4 weeks following transplantation of cord blood transduced with vectors expressing BCR-ABL1 and a dominant-negative isoform of IKAROS, Ik6. "
5.	Immunotherapy 01/01/1985 - "[Autogenic anti-idiotypic suppression of autoimmune reactions--a new approach to immunotherapy of experimental leukemia]." 09/01/1973 - "Immunology and colonic cancer: cancer immunotherapy results in leukemias--experimental and clinical approaches to the treatment of solid tumors."